A retrospective Taiwanese study showed that the use of a GLP-1 receptor agonist was associated with a lower risk of repeated serious adverse limb effects (MALE) in people with diabetes compared with another class of drugs. The study included 17,288 patients with diabetes for whom new data were added. GLP-1 drugs thus reduce the risk of amputation in diabetes. The results suggest an advantage of GLP-1 agonists over alternative drugs in the prevention of serious lower limb complications. The study was published on MedPage Today.